June 2026 Research Update

This month added more real-world evidence that treatments aimed at the MAPK pathway (a growth signaling pathway often turned on in ECD) can shrink or control disease for many people, but tolerability varies. In a UK cohort, trametinib (a MEK inhibitor) was linked to clinical improvement in many patients, and imaging also improved in a majority, with side effects often managed by changing or pausing treatment. Several single-patient reports in ECD echoed that targeted approaches can help, including in BRAF V600E-mutant and non-BRAF-V600E disease. [1] [2] [3] [4]

In the multicenter UK cohort of histiocytic neoplasms (including ECD), 30 of 37 people were reported to have a clinical response to trametinib-based therapy, and 25 of 37 had a radiology response at a median follow-up of 21.4 months. Side effects were common, especially skin and stomach or bowel symptoms, and 5 people stopped treatment due to severe toxicity; 2 deaths occurred within 6 months, though the report does not establish why those deaths occurred. The cohort also suggested fewer non-responders in those receiving trametinib plus dabrafenib than trametinib alone, but this was not a randomized comparison. [4]

In an ECD case with liver involvement and non-BRAF-V600E disease, trametinib was followed by rapid improvement in liver blood tests after 1 month, and liver lesions looked improved on follow-up Ga-FAPI PET/CT at 6 and 12 months, although the patient still had persistent high urine output. This supports the idea that a MEK inhibitor can sometimes help even when BRAF V600E is not present, but it is still a single-person result and may not apply to everyone. [1]

Two BRAF V600E-mutant ECD reports described disease control with BRAF-targeted treatment, while also showing that side effects can shape which drug a person can stay on. One person had stable disease at 1 year on vemurafenib after a rash led to dose reduction, and another person could not tolerate vemurafenib (with problems such as falls and neuropathy) but reported clinical improvement after switching to dabrafenib plus trametinib. These reports reinforce why mutation testing matters in ECD and why more than one targeted option may be considered in research and specialist settings. [2] [3]

For patients and caregivers, the main update is that targeted treatments used in real-world settings continue to show meaningful disease improvement for many people with histiocytic conditions, including ECD, but side effects and individual differences remain a major part of the story. The strongest evidence this month came from the UK cohort of 37 patients treated with trametinib-based therapy, while the ECD-specific reports were single cases that illustrate what can happen rather than what will happen. What remains uncertain is which targeted approach works best for which ECD subtype and mutation, and how to predict or prevent treatment-limiting side effects. This information mainly adds to the evidence base and the understanding of options being studied and used in specialty care, rather than changing anything on its own. [4] [1] [2] [3]

This month made ECD diagnosis feel more "toolbox-based": combining imaging that maps disease around the body with biopsy approaches that can confirm histiocytosis and sometimes detect treatable mutations. A lung-focused retrospective study supported transbronchial lung cryobiopsy as a less invasive way to reach a diagnosis in many patients with lung-involved histiocytosis, although it did not match surgical biopsy in diagnostic success. Case reports reinforced that ECD can first show up in organs like the heart sac (pericardium) or the pituitary area, and that recognizing classic imaging patterns can speed diagnosis when symptoms are confusing. [5] [6] [7]

In patients with lung inflammatory myeloid neoplasms (including ECD and LCH), transbronchial lung cryobiopsy provided a diagnosis in 17 of 21 cases, compared with 7 of 7 for surgical lung biopsy. Genetic testing was feasible in 9 cryobiopsy samples, and MAPK-pathway mutations were identified in 3 patients, which matters because mutations can guide targeted treatments. Pneumothorax occurred in 3 patients undergoing cryobiopsy (reported in PLCH), and it was managed with chest tubes, emphasizing that less invasive does not mean risk-free. [5]

Several ECD case reports showed how whole-body and organ-focused imaging can point toward the diagnosis when the first symptom is in a high-risk organ. One patient presented with pericardial tamponade, and imaging described classic signs like a "coated aorta" and "hairy kidney" plus long-bone involvement, which helped connect heart symptoms to a multisystem disease. Another report comparing FDG-PET/CT with NaF-PET/CT suggested that NaF-PET/CT can visualize osteosclerotic bone lesions particularly well, while FDG-PET/CT tracked changes in inflammatory activity after treatment. [6] [8]

A central nervous system presentation added a reminder that biopsy and mutation testing can be challenging when disease is in the brain or pituitary region. In one person with a rapidly enlarging suprasellar mass causing diabetes insipidus and multiple hormone failures, an initial biopsy was inconclusive and a later biopsy identified BRAF V600E-mutant disease consistent with ECD. The report underscores that limited tissue sampling can delay a clear diagnosis in some settings, even when imaging strongly suggests serious disease in the pituitary area. [7]

For patients, these studies help explain why ECD workups often involve more than one scan and why a biopsy may be needed to confirm the diagnosis and check for mutations. The lung cryobiopsy study suggests a less invasive biopsy method can often work and can sometimes provide enough tissue for mutation testing, though it may not succeed every time and can have complications like pneumothorax. The case reports show how ECD can be recognized through a combination of organ symptoms (like pericardial fluid or hormone problems) plus characteristic imaging patterns and tissue staining, but they also show that diagnosis can still be delayed when tissue is hard to obtain. This body of evidence may matter now mainly by clarifying the diagnostic process patients may experience, rather than proving one best pathway for everyone. [5] [6] [8] [7]

This month expanded the picture of how varied ECD can look, especially in the skin and in less typical organ patterns. One clinical series tied a specific set of vascular skin growths to markedly high VEGF-A levels, suggesting these lesions are driven by signals released by ECD cells rather than by mutations in blood vessel cells themselves. Separate case reports described uncommon major-organ patterns, where delays or gaps in molecular testing limited the ability to match patients to targeted treatments in time. [9] [10]

In a small subset of ECD patients, glomeruloid hemangiomas and extensive angiomas were reported together with markedly elevated VEGF-A, even without POEMS syndrome. Molecular work suggested the ECD histiocytes showed MAPK activation, while the cells lining the blood vessels did not show their own mutations, supporting a "paracrine" explanation where ECD cells may be sending out signals that promote extra blood vessel growth. This gives patients a clearer explanation for why unusual blood vessel-like skin lesions can occur in ECD and how they may connect to body-wide signaling. [9]

Two reported ECD cases with unusual dominant involvement (one mainly gastrointestinal, one with constrictive pericarditis and thickened pleura) still showed classic multisystem imaging clues such as "hairy kidney," "coated aorta," and symmetric long-bone changes. Both patients died during the reported course, and the authors noted that BRAF V600E testing was not completed, which limited targeted therapy decisions. These cases highlight how ECD can be hard to recognize when it starts in an unexpected place, and how incomplete mutation testing can become a practical barrier. [10]

One additional case report in the input described an eye condition that can mimic histiocytosis in the tissue staining pattern, but a thorough systemic evaluation excluded Erdheim-Chester disease. The report helps show that not all xanthogranulomatous (foamy-histiocyte) lesions of the eye are ECD, even when pathology looks similar, and it illustrates the role of systemic workup when ECD is considered. [11]

For patients, this set of studies mainly adds understanding of the range of ways ECD can appear, including skin findings and unexpected organ involvement. The VEGF-A report may matter most in the future, by clarifying a possible biological explanation for certain vascular skin lesions and by pointing to a measurable blood marker that tracked with those lesions in that series. The unusual-case reports matter now mostly by explaining why some people experience long diagnostic journeys when symptoms start outside the bones, and why mutation testing can be important but is not always completed quickly. None of these reports can predict an individual person's course, because they describe small numbers of patients and rare presentations. [9] [10] [11]